No one who follows PKI closely would ever characterize it as “an X-ray manufacturer,” implying that X-ray machines are a dominant portion of the company's revenue. As I said in a prior post, this is like calling INTC a “software company.”
In fact, PKI is a highly diversified biotech company where no single product line or service offering comprises more than about 15% of overall sales. The lack of understanding of the manifold business lines is probably one reason that PKI is undervalued.
Market Data 
Markets 
AI
